Genetics Quiz
Practice Transcription Factors And Expression in Genetics with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.
Question 1 / 20
0 of 20 answered
A gene's promoter contains a low-affinity binding site for an activator, TF-A, and a high-affinity binding site for a repressor, TF-R. In cells expressing low levels of both TFs, the gene is off. If the expression of only TF-A is strongly induced to high levels, what is the most likely outcome for gene transcription?
This quiz focuses on Transcription Factors And Expression, giving you a quick way to practice the rules, question types, and explanations that matter most for Genetics.
Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.
A gene's promoter contains a low-affinity binding site for an activator, TF-A, and a high-affinity binding site for a repressor, TF-R. In cells expressing low levels of both TFs, the gene is off. If the expression of only TF-A is strongly induced to high levels, what is the most likely outcome for gene transcription?
Explanation: When you encounter gene regulation problems, focus on how transcription factor concentration and binding affinity work together to determine transcriptional outcomes. The key principle is that high concentrations of a transcription factor can overcome low binding affinity through mass action effects. In this scenario, dramatically increasing TF-A concentration creates a situation where the activator can effectively compete for gene regulation despite its low-affinity binding site. While TF-R has higher affinity, it remains at low levels and cannot effectively repress transcription when faced with abundant TF-A molecules. The high concentration of TF-A means many activator molecules are available to bind even the low-affinity site, driving robust gene expression. Answer A incorrectly assumes that binding affinity alone determines the outcome, ignoring concentration effects. This represents a common misconception that affinity is the only factor in protein-DNA interactions. Answer B suggests some complex temporal regulation pattern that isn't supported by the given information—there's no mechanism described for permanent silencing. Answer C assumes the effects will balance out, but this ignores that TF-R remains at low levels while TF-A is highly abundant, creating an imbalanced competition. The correct answer is D because transcription factor effectiveness depends on both concentration and affinity. High concentrations can compensate for low affinity through increased binding probability. For genetics exams, remember that gene regulation questions often test whether you understand the interplay between transcription factor concentration and binding affinity. Don't assume that affinity alone determines binding outcomes—concentration matters enormously in biological systems.
The gene INS is regulated by an enhancer that is active only in pancreatic beta cells. This enhancer integrates signals from three different activator transcription factors: PDX1, NEUROD1, and MAFA. Loss-of-function mutations in any one of these factors can lead to diabetes due to insufficient INS expression. This indicates which principle of transcriptional regulation?
Explanation: When you encounter questions about multiple transcription factors controlling a single gene, you're dealing with gene regulatory mechanisms that determine when and where genes are expressed. The correct answer is A because this scenario perfectly illustrates combinatorial control. The INS gene requires all three transcription factors (PDX1, NEUROD1, and MAFA) working together to achieve proper expression in pancreatic beta cells. The key evidence is that losing any one factor causes diabetes due to insufficient insulin production. This means each factor is necessary, and together they're sufficient for normal gene expression. Combinatorial control allows cells to achieve precise, tissue-specific gene expression by requiring specific combinations of regulatory proteins. B is incorrect because lateral inhibition describes a developmental process where neighboring cells inhibit each other's differentiation, not transcription factor interactions at a single gene promoter. C is wrong because redundancy would mean the factors could substitute for each other. If that were true, losing one factor wouldn't cause diabetes since the others could compensate. The fact that each individual loss causes disease proves they're not redundant. D is incorrect because feedback inhibition involves the gene product (insulin) regulating its own transcription factors. The question describes how transcription factors regulate the gene, not how the gene product affects those factors. Study tip: Remember that combinatorial control is a hallmark of eukaryotic gene regulation. When you see multiple factors required for one gene's expression, and losing any single factor has severe consequences, think combinatorial control.
The expression of gene Z is regulated by two transcription factors: TF-Alpha (an activator) and TF-Beta (a repressor). They bind to adjacent, non-overlapping sites in the gene's promoter. High expression of gene Z requires TF-Alpha to be bound and TF-Beta to be unbound. In a specific cell line, a mutation renders TF-Alpha completely unable to bind DNA. Simultaneously, an experimental condition reduces the cellular concentration of TF-Beta by 50%. What is the predicted change in the transcription of gene Z?
Explanation: The premise states that the binding of TF-Alpha is required for high expression. Since the mutant TF-Alpha cannot bind DNA, this necessary condition for activation is not met. The reduction in the repressor (TF-Beta) is irrelevant because the activation pathway is completely blocked. Therefore, transcription will be at a minimal basal level or completely abolished.
The transcription factor HES1 represses the transcription of its own gene, HES1, by binding to its promoter. This autorepression creates a negative feedback loop. What is the primary functional consequence of this regulatory circuit on the cellular levels of HES1 protein over time?
Explanation: A negative feedback loop where a protein represses its own transcription is a common motif for generating oscillations. As HES1 protein is made, it accumulates and shuts off its own gene. The existing protein is then degraded, its concentration falls, and the repression is lifted, allowing transcription to begin again. This cycle of production and repression leads to periodic pulses of HES1, which is critical for processes like neuron development.
The repressor protein MeCP2 binds to methylated DNA and suppresses transcription. Its repressive function depends on its ability to recruit a Histone Deacetylase (HDAC) complex. A patient has a mutation in MeCP2 that prevents it from interacting with the HDAC complex, but its ability to bind methylated DNA is unaffected. How would this mutation most likely affect the expression of MeCP2 target genes?
Explanation: MeCP2's function requires two steps: binding to methylated DNA and recruiting HDACs to condense chromatin. The mutation disrupts the second step. Although MeCP2 can still bind, it can no longer recruit the machinery that causes chromatin condensation and transcriptional repression. The result is a loss of repression, leading to inappropriate or higher-than-normal expression of its target genes.
The gene Myosin is expressed only in muscle cells. Its enhancer contains binding sites for three transcription factors: TF-U (ubiquitously expressed), TF-M1 (muscle-specific), and TF-M2 (muscle-specific). Experimental evidence suggests that binding of all three TFs is necessary for high levels of transcription. The gene Actin, required in all cells, is activated by TF-U alone. Which statement accurately predicts the expression of these genes in a skin cell?
Explanation: Skin cells, like most cells, will express the ubiquitous transcription factor TF-U. Since TF-U alone is sufficient to activate Actin, this gene will be expressed. However, skin cells do not express the muscle-specific factors TF-M1 and TF-M2. Because all three factors are required for Myosin expression, the absence of the muscle-specific factors means Myosin will remain silent in skin cells.
The transcription factor CREB activates target genes by forming a homodimer and binding to the cAMP response element (CRE). A researcher discovers a mutation in the CREB gene, named CREB-DN, which produces a protein that can dimerize with wild-type CREB but whose DNA-binding domain is non-functional. If a heterozygous individual has one wild-type CREB allele and one CREB-DN allele, what is the expected functional level of CREB activity compared to a wild-type homozygote, assuming equal protein expression and random dimerization?
Explanation: In a heterozygote, there are two types of CREB proteins: wild-type (WT) and mutant (DN). They can form three types of dimers: WT-WT, WT-DN, and DN-DN. Only the WT-WT dimer is functional for DNA binding. Assuming a 1:1 ratio of proteins, random dimerization yields a 1:2:1 ratio of WT-WT : WT-DN : DN-DN dimers. Thus, only 25% of the dimers are functional. This is a dominant negative effect, where the mutant protein poisons the wild-type protein, resulting in activity significantly below the 50% expected from simple haploinsufficiency.
The glucocorticoid receptor (GR) is a transcription factor that resides in the cytoplasm. Upon binding its ligand, cortisol, GR translocates to the nucleus and activates target genes. A patient has a mutation in the GR gene that causes the receptor to be constitutively localized in the nucleus, even in the absence of cortisol. However, the mutant GR still requires cortisol binding to its ligand-binding domain to adopt an active conformation for transcription. How will this patient's target gene expression respond to cortisol?
Explanation: In a wild-type cell, there is a time lag for activation as GR must first bind cortisol and then translocate to the nucleus. In the mutant, the receptor is already in the nucleus, co-localized with its target genes. The rate-limiting step of nuclear translocation has been eliminated. Therefore, upon cortisol administration, the receptor can become activated and initiate transcription more rapidly and efficiently, leading to a faster and stronger response.
The transcription factor MyoD must form a heterodimer with a ubiquitously expressed E protein to bind DNA and activate muscle-specific genes. A researcher introduces a synthetic MyoD variant into non-muscle cells. This variant contains a mutation in its dimerization domain that forces it to form MyoD-MyoD homodimers, which cannot bind the target DNA sequence. What is the expected outcome in these cells?
Explanation: MyoD's function as a master regulator of myogenesis is critically dependent on its ability to form a functional heterodimer with an E protein, which can then bind DNA. The engineered variant forms homodimers that are explicitly stated to be incapable of DNA binding. Therefore, the variant protein is non-functional, and the downstream muscle differentiation program will not be initiated.
The transcription factor NF-κB is a key activator of immune response genes. In unstimulated cells, it is sequestered in the cytoplasm by its inhibitor, IκB. Upon signaling, IκB is degraded, allowing NF-κB to translocate to the nucleus. What would be the most likely consequence of a mutation in NF-κB that disrupts its nuclear localization signal (NLS) but does not affect its interaction with IκB or its ability to bind DNA?
Explanation: The function of a transcription factor depends on its ability to reach its target DNA in the nucleus. In this scenario, NF-κB is properly released from its inhibitor IκB upon signaling. However, due to the defective NLS, it cannot be imported into the nucleus. Because it remains in the cytoplasm, it cannot access its target genes, and the immune response fails to be activated.
Pioneer transcription factor FoxA1 can bind to its target DNA sequences even within highly condensed, closed chromatin. This binding initiates chromatin remodeling, making it accessible to other factors. The gene Albumin requires both FoxA1 and another transcription factor, HNF4α, for expression. HNF4α cannot bind to condensed chromatin. In a liver cell line where the FoxA1 gene has been knocked out, what is the expected status of the Albumin gene locus and its expression, assuming HNF4α is present?
Explanation: FoxA1 acts as a pioneer factor, meaning its primary role is to open condensed chromatin to allow other factors to bind. Without FoxA1, the Albumin regulatory region will remain inaccessible. Since HNF4α cannot bind to closed chromatin, it will be unable to access its binding sites. Therefore, the gene will not be activated, and the chromatin will remain in a closed state.
Humans and chimpanzees share a nearly identical protein-coding sequence for the FOXP2 gene. However, the timing and level of its expression in the developing brain differ significantly between the two species. This difference in expression is hypothesized to contribute to uniquely human language abilities. What is the most likely genetic basis for this species-specific difference in FOXP2 regulation?
Explanation: When the protein product of a gene is conserved but its expression pattern has diverged, the most likely cause is evolution of the cis-regulatory elements (e.g., enhancers, promoters, silencers). These non-coding sequences control when, where, and how much a gene is transcribed. Changes in these elements can alter TF binding and lead to new expression patterns without changing the protein itself. Changes in trans-factors or general machinery would likely affect many genes, not just one.
A researcher identifies a novel transcription factor, Repressor-Y (RepY), that silences gene expression. Experimental data show that RepY binding to a silencer element leads to the trimethylation of Histone H3 at Lysine 27 (H3K27me3), a repressive chromatin mark, at the target gene's promoter. Which of the following proteins is RepY most likely recruiting to the silencer element to mediate this effect?
Explanation: When you encounter questions about gene silencing and chromatin modifications, focus on the relationship between transcriptional repressors and the chromatin-modifying enzymes they recruit to establish repressive marks. RepY is causing H3K27me3, a well-known repressive histone mark, to appear at target promoters. Since RepY itself is just a DNA-binding transcription factor, it must be recruiting other proteins to actually create this chromatin modification. To generate H3K27me3, you need an enzyme that adds methyl groups specifically to lysine 27 of histone H3 - this is exactly what a histone methyltransferase (HMT) specific for H3K27 does. Choice A correctly identifies the enzyme class responsible for creating the observed modification. Choice B is incorrect because Mediator complex components facilitate transcriptional activation by helping RNA polymerase II initiation, not gene silencing. Choice C represents the opposite of what's needed - histone acetyltransferases (HATs) add acetyl groups that generally promote transcriptional activation, not the repression described here. Choice D would actually remove the H3K27me3 marks rather than create them, since histone demethylases (HDMs) remove methyl groups from histones. Remember this pattern: when a question describes a specific chromatin modification appearing after transcription factor binding, the transcription factor is recruiting the enzyme that creates that modification. Match the modification type (methylation, acetylation, etc.) with the corresponding enzyme class, and consider whether the mark is activating or repressive to determine the correct direction of the enzymatic activity.
Gene GLP1 expression is activated by the transcription factor Activator-X (ActX). ActX has a DNA-binding domain (DBD) and an activation domain (AD). A researcher creates a mutant version of ActX (ActX-mut) that has a functional DBD but a non-functional AD. This ActX-mut is overexpressed in cells that also contain wild-type ActX. Assuming ActX-mut and wild-type ActX compete for the same DNA binding site on the GLP1 regulatory element, what is the most likely effect on GLP1 transcription?
Explanation: The mutant ActX-mut can bind to the DNA regulatory element using its functional DBD, but it cannot activate transcription because its AD is non-functional. By occupying the binding site, it prevents the functional wild-type ActX from binding. This phenomenon is known as a dominant negative effect or competitive inhibition, leading to a decrease in gene expression.
The transcription factor TFE is an activator that must be phosphorylated by Kinase-K to bind to an enhancer and activate gene CYC. A cell line has a loss-of-function mutation in the phosphatase that normally dephosphorylates TFE. Assuming Kinase-K has some basal activity, what is the expected phenotype regarding CYC expression in this mutant cell line compared to wild-type?
Explanation: In wild-type cells, the level of active (phosphorylated) TFE is a balance between Kinase-K activity and phosphatase activity. A loss-of-function mutation in the phosphatase eliminates the 'off' switch. Even basal activity of Kinase-K will lead to the accumulation of phosphorylated, active TFE, which will persistently activate CYC expression, making it constitutively high.
The expression of gene Z is regulated by two transcription factors: TF-Alpha (an activator) and TF-Beta (a repressor). They bind to adjacent, non-overlapping sites in the gene's promoter. High expression of gene Z requires TF-Alpha to be bound and TF-Beta to be unbound. In a specific cell line, a mutation renders TF-Alpha completely unable to bind DNA. Simultaneously, an experimental condition reduces the cellular concentration of TF-Beta by 50%. What is the predicted change in the transcription of gene Z?
Explanation: The premise states that the binding of TF-Alpha is required for high expression. Since the mutant TF-Alpha cannot bind DNA, this necessary condition for activation is not met. The reduction in the repressor (TF-Beta) is irrelevant because the activation pathway is completely blocked. Therefore, transcription will be at a minimal basal level or completely abolished.
The transcription factor CREB activates target genes by forming a homodimer and binding to the cAMP response element (CRE). A researcher discovers a mutation in the CREB gene, named CREB-DN, which produces a protein that can dimerize with wild-type CREB but whose DNA-binding domain is non-functional. If a heterozygous individual has one wild-type CREB allele and one CREB-DN allele, what is the expected functional level of CREB activity compared to a wild-type homozygote, assuming equal protein expression and random dimerization?
Explanation: In a heterozygote, there are two types of CREB proteins: wild-type (WT) and mutant (DN). They can form three types of dimers: WT-WT, WT-DN, and DN-DN. Only the WT-WT dimer is functional for DNA binding. Assuming a 1:1 ratio of proteins, random dimerization yields a 1:2:1 ratio of WT-WT : WT-DN : DN-DN dimers. Thus, only 25% of the dimers are functional. This is a dominant negative effect, where the mutant protein poisons the wild-type protein, resulting in activity significantly below the 50% expected from simple haploinsufficiency.
Gene GLP1 expression is activated by the transcription factor Activator-X (ActX). ActX has a DNA-binding domain (DBD) and an activation domain (AD). A researcher creates a mutant version of ActX (ActX-mut) that has a functional DBD but a non-functional AD. This ActX-mut is overexpressed in cells that also contain wild-type ActX. Assuming ActX-mut and wild-type ActX compete for the same DNA binding site on the GLP1 regulatory element, what is the most likely effect on GLP1 transcription?
Explanation: The mutant ActX-mut can bind to the DNA regulatory element using its functional DBD, but it cannot activate transcription because its AD is non-functional. By occupying the binding site, it prevents the functional wild-type ActX from binding. This phenomenon is known as a dominant negative effect or competitive inhibition, leading to a decrease in gene expression.
The transcription factor TFE is an activator that must be phosphorylated by Kinase-K to bind to an enhancer and activate gene CYC. A cell line has a loss-of-function mutation in the phosphatase that normally dephosphorylates TFE. Assuming Kinase-K has some basal activity, what is the expected phenotype regarding CYC expression in this mutant cell line compared to wild-type?
Explanation: In wild-type cells, the level of active (phosphorylated) TFE is a balance between Kinase-K activity and phosphatase activity. A loss-of-function mutation in the phosphatase eliminates the 'off' switch. Even basal activity of Kinase-K will lead to the accumulation of phosphorylated, active TFE, which will persistently activate CYC expression, making it constitutively high.
The transcription factor NF-κB is a key activator of immune response genes. In unstimulated cells, it is sequestered in the cytoplasm by its inhibitor, IκB. Upon signaling, IκB is degraded, allowing NF-κB to translocate to the nucleus. What would be the most likely consequence of a mutation in NF-κB that disrupts its nuclear localization signal (NLS) but does not affect its interaction with IκB or its ability to bind DNA?
Explanation: The function of a transcription factor depends on its ability to reach its target DNA in the nucleus. In this scenario, NF-κB is properly released from its inhibitor IκB upon signaling. However, due to the defective NLS, it cannot be imported into the nucleus. Because it remains in the cytoplasm, it cannot access its target genes, and the immune response fails to be activated.